Intermittent androgen suppression is neither inferior nor superior to continuous therapy for cancer control, but has significant advantages in respect to adverse effects, quality of life and cost. In this Review the authors present the key evidence supporting the efficacy of intermittent androgen suppression, and highlight how current data can be applied to everyday clinical practice.
- Nicholas C. Buchan
- S. Larry Goldenberg
